The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat 2019/01/06–Immunotherapy: What Patients Need To Know
- #LCSM Chat 11/29: What’s a cancer model, and why should I care?
- #LCSM Chat Topic 11/15/2018: #LCAM Open Mic Nite
- #LCSM Chat Topic 11/1: #LCAM and the Evolution of Lung Cancer Advocacy
- #LCSM Chat Topic 10/18/2018: Lung Cancer Screening: Never a Better Time Than Now
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials Drugs EGFR epatients FDA immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day